Logo Medical Science Monitor

Call: +1.631.470.9640
Closed: National Holiday

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 October 2005

Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia: Final report of the Polish Adult Leukemia Group (PALGCLL1).

Tadeusz Robak, Jerzy Z Błoński, Marek Kasznicki, Joanna Góra-Tybor, Anna Dmoszyńska, Maria Wojtaszko, Aleksander B Skotnicki, Wiesław Nowak, Andrzej Hellmann, Krzysztof Lewandowski, Barbara Zdziarska, Lech Konopka, Bernadetta Ceglarek, Jadwiga Dwilewicz-Trojaczek, Piotr Boguradzki, Kazimierz Kuliczkowski, Kazimierz Sułek, Krzysztof Warzocha

Med Sci Monit 2005; 11(10): PI71-79 :: ID: 430316

Abstract

BACKGROUND: We previously published an early report of a randomized, multicentertrial on the efficacy and toxicity of cladribine (2-CdA) + prednisone (P) compared with chlorambucil(Chl) + P in previously untreated patients with progressive or symptomatic chronic lymphocytic leukemia.Here we present the final report of this study. MATERIAL/METHODS: Of 229 patients, 126 received 2-CdA+Pand 103 Chl+P. Patients with no response or progression after three courses or who relapsed earlier than12 months after completing one treatment were switched to the other. Patients who relapsed later wereretreated with the same schedule as before. RESULTS: Thirty-three patients were retreated with 2-CdA+Pand 19 with Chl+P. Overall response (and complete response) rates were 35% (6%) and 47% (16%), respectively.In 50 patients initially treated with Chl+P and then with 2-CdA+P, complete response (CR) was achievedin 12 (24%) and overall response (OR) in 32 (64%). In 28 patients originally treated with 2-CdA+P andthen with Chl+P, CR in 1 (3%, p=0.01) and OR in 6 (21%, p=0.003) were obtained. We found no statisticallysignificant difference in overall survival time in patients treated initially with 2-CdA+P and Chl+Paged 60 years (4.63 and 5.27 years, respectively, p=0.45), 60-70 years (3.29 and 3.14 years, p=0.79),and >70 years (1.53 and 1.93 years, p=0.11). CONCLUSIONS: 2-CdA+P is significantly more effective asa second-line treatment and re-treatment than Chl+P. However, we found a trend to longer survival inelderly patients treated with Chl+P.

Keywords: Cladribine - administration & dosage, Chlorambucil - administration & dosage, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Cyclophosphamide - administration & dosage, Doxorubicin - administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy, Prednisone - administration & dosage, Survival Analysis, Vincristine - administration & dosage

Add Comment 0 Comments

667 8

Editorial

01 May 2023 : Editorial  

Editorial: Twenty Years On from Sequencing the Human Genome, Personalized/Precision Oncology Prepares to Meet the Challenges of Checkpoint Inhibitor Therapy

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.940911

Med Sci Monit 2023; 29:e940911

In Press

28 May 2023 : Database Analysis  

Scientometric and Visualized Analysis of Intravoxel Incoherent Motion Magnetic Resonance Imaging: 1988-2021

Med Sci Monit In Press; DOI: 10.12659/MSM.938715  

25 May 2023 : Database Analysis  

The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in Poland

Med Sci Monit In Press; DOI: 10.12659/MSM.940904  

25 May 2023 : Review article  

A Review of Preclinical and Clinical Studies in Support of the Role of Non-Steroidal Anti-Inflammatory Drug...

Med Sci Monit In Press; DOI: 10.12659/MSM.940635  

25 May 2023 : Clinical Research  

Periapical Lesions and Missed Canals in Endodontically Treated Teeth: A Cone-Beam Computed Tomographic Stud...

Med Sci Monit In Press; DOI: 10.12659/MSM.940533  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750